Avedro

The World Leader in Corneal Crosslinking Science

Main menu

Skip to primary content
Skip to secondary content
  • Home
  • About Avedro
    • About Avedro
    • Management Team
    • Board of Directors
    • Medical Advisory Board
    • Investors
    • Careers
      • Current Openings
    • Contact Us
  • Products
    • KXL
    • Riboflavin Family
      • VibeX™
      • VibeX Rapid™
      • VibeX Xtra™
      • ParaCel™
  • Procedures
    • Lasik Xtra®
    • Accelerated Crosslinking
  • Science
    • Cross-linking Science
    • White Papers
    • KXL Book
    • Clinical Trials
  • News & Events
    • News and Articles
    • Press Releases
    • Events
    • Videos

Videos

Videos

Lasik Xtra®

Accelerated Cross-linking for Keratoconus, Ectasia, and other Applications

Lasik Xtra®

Global Advances in Corneal Cross-linking, OSN Video Perspective with Gustavo Tamayo, MD

A. John Kanellopoulos, MD discusses the Lasik Xtra procedure

Eyetube.net : Refractive Surgery Technologies – Nanosecond Laser and Crosslinking

BACK

Accelerated Cross-linking for Keratoconus, Ectasia, and other Applications

Femto Astigmatic Keratototmy with High Fluence CXL (Femto AK Xtra), by A. John Kanellopoulos, MD 

Cataract Accelerated Cross-linking Video, by A. John Kanellopoulos, MD 

EyewireTV – Avedro CXL Patents

EyewireTV — ACOS CXL Trial Begins

Eyewire Today – In this week’s EyewireTV News, the FDA grants Avedro Inc. orphan drug designation for its riboflavin ophthalmic solution, known as VibeX, for use with its KXL system for corneal cross-linking to treat keratoconus. September 2011

 

BACK

 

 

Avedro products are not for sale in the United States.  
MA-00123F
  • News and Articles
  • Press Releases
  • Events
  • Videos

  • Home
  • About Avedro
  • Products
  • Procedures
  • Science
  • News & Events
  • Terms of Use
  • Contact Us
Copyright © 2013, Avedro, Inc. | Web site by: Partridge Design